REG - Destiny Pharma PLC - Director Dealing

Destiny PharmaAnnouncement

26/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ7229Aa&default-theme=true

RNS Number : 7229A  Destiny Pharma PLC  26 May 2023

 

 

 

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Director Dealing

 

 

Brighton, United Kingdom - 26 May 2023 - Destiny Pharma plc (AIM: DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
on 25 May 2023, certain Directors of the Company have purchased ordinary
shares (the "Purchases") of 1 pence each in the Company ("Ordinary Shares").
Full details of the Purchases are detailed in the table below.

 Director       Position                         Ordinary Shares Purchased  Purchase Price  Resultant Holding  % of total voting rights
 Nick Rodgers   Chairman                         14,780                     30.35 pence     218,901            0.23%

                                                 49,477                     31 pence
 Debra Barker   Interim Chief Executive Officer  20,000                     33 pence        88,461             0.09%
 Aled Williams  Non-Executive Director           50,000                     31 pence        50,000             0.05%

 

 

For further information, please contact:

 

Destiny Pharma plc

Dr Debra Barker, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

 

 

 

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has completed a positive Phase 2 clinical trial targeting the prevention of
post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention
of COVID-19 and other viral respiratory infections and has earlier grant
funded XF drug research projects.

 

For further information on the Company, please visit
https://www.destinypharma.com (https://www.destinypharma.com)

 

 

 

Further information is disclosed below pursuant to Article 19(3) of the Market
Abuse Regulation.

 

 1.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Nick Rodgers
 2.                        Reason for the Notification
 a)                        Position/status                                              Chairman
 b)                        Initial notification/Amendment                               Initial Notification
 3.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Destiny Pharma plc
 b)                        LEI                                                          213800O9WH9Z38EHAC95
 4.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each in Destiny Pharma Plc
                           Identification code                                          GB00BDHSP575
 b)                        Nature of the transaction                                    Purchase of Ordinary Shares
 c)                        Price(s) and volume(s)                                       Price(s)     Volume(s)
                                                                                        30.35 pence  14,780

                                                                                        31 pence     49,477
 d)                        Aggregated information:

                           ·      Aggregated volume                                     See 4c) above

                           ·      Price
 e)                        Date of the transaction                                      25 May 2023
 f)                        Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See 4c) above

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 5.                        Details of the person discharging managerial responsibilities / person closely
                           associated
 a)                        Name                                                         Debra Barker
 6.                        Reason for the Notification
 a)                        Position/status                                              Interim Chief Executive Officer
 b)                        Initial notification/Amendment                               Initial Notification
 7.                        Details of the issuer, emission allowance market participant, auction
                           platform, auctioneer or auction monitor
 a)                        Name                                                         Destiny Pharma plc
 b)                        LEI                                                          213800O9WH9Z38EHAC95
 8.                        Details of the transaction(s): section to be repeated for (i) each type of
                           instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                           place where transactions have been conducted
 a)                        Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each in Destiny Pharma Plc
                           Identification code                                          GB00BDHSP575
 b)                        Nature of the transaction                                    Purchase of Ordinary Shares
 c)                        Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                                        33 pence  20,000
 d)                        Aggregated information:

                           ·      Aggregated volume                                     See 4c) above

                           ·      Price
 e)                        Date of the transaction                                      25 May 2023
 f)                        Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See 4c) above

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 9.                         Details of the person discharging managerial responsibilities / person closely
                            associated
 a)                         Name                                                         Aled Williams
 10.                        Reason for the Notification
 a)                         Position/status                                              Non-Executive Director
 b)                         Initial notification/Amendment                               Initial Notification
 11.                        Details of the issuer, emission allowance market participant, auction
                            platform, auctioneer or auction monitor
 a)                         Name                                                         Destiny Pharma plc
 b)                         LEI                                                          213800O9WH9Z38EHAC95
 12.                        Details of the transaction(s): section to be repeated for (i) each type of
                            instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                            place where transactions have been conducted
 a)                         Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each in Destiny Pharma Plc
                            Identification code                                          GB00BDHSP575
 b)                         Nature of the transaction                                    Purchase of Ordinary Shares
 c)                         Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                                         31 pence  50,000
 d)                         Aggregated information:

                            ·      Aggregated volume                                     See 4c) above

                            ·      Price
 e)                         Date of the transaction                                      25 May 2023
 f)                         Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See 4c) above

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFLREAIEFIV